Regenxbio Inc (RGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $505.18M
Last updated: Nov 17, 2026 at 4:15 PM ET
Regenxbio Inc (RGNX) Statistics
Regenxbio (RGNX) has a market cap of $505.18M and an enterprise value of $409.38M. Its share count is up 26.26% from a year earlier. It kept -113.85% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 18.96% below the market cap, as cash exceeds debt.
| Market Cap | $505.18M |
|---|---|
| Enterprise Value | $409.38M |
| Latest price (Nov 17, 2026) | $7.24 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.1x and 3.2x. Its year-end P/S ranged from 4.4x to 106.7x from 2016 to 2025.
| P/S Ratio | 3.1x |
|---|---|
| Forward P/S | 3.2x |
| P/B Ratio | 3.2x |
Price Statistics
The stock is down 37.10% over 52 weeks and trades 4.61% below its 50-day average.
| Beta (1Y) | 1.81 |
|---|---|
| 52-Week Change | -37.10% |
| 1-Month Change | +1.26% |
| 3-Month Change | -39.77% |
| 6-Month Change | +27.92% |
| 5-Year Change | -79.68% |
| 10-Year Change | -54.29% |
| Total Return (1Y) | -37.10% |
| Total Return (3Y CAGR) | -28.11% |
| Total Return (5Y CAGR) | -25.73% |
| Return vs SPY (1Y) | -47.20% |
| Max Drawdown (1Y) | -64.64% |
| Max Drawdown (3Y) | -78.42% |
| Sharpe Ratio (1Y) | -0.45 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $7.59 |
| 200-Day Average | $8.84 |
| 52-Week Range | $5.46 to $16.19 |
| RSI (14 Days) | 45.8 |
| Average Volume (20 Days) | 1.25M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.74x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.74x |
|---|---|
| Quick Ratio | 4.74x |
| Debt / Equity | 0.00x |
| Interest Coverage | -4.06x |
Returns and Efficiency
Return on equity is -118.36% over the last 12 months, against a 5-year average of -79.66%.
| Return on Equity (ROE) | -118.36% |
|---|---|
| Return on Assets (ROA) | -37.60% |
| Return on Capital Employed (ROCE) | -36.95% |
| ROE (5Y Average) | -79.66% |
| ROA (5Y Average) | -31.92% |
| Asset Turnover | 0.31x |
| Receivables Turnover | 2.67x |
Scores
RGNX has an Altman Z-Score of -2.88, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.88 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $153.91M over the last 12 months is down 4.59% from the 12 months before.
| Revenue | $153.91M |
|---|---|
| Revenue Growth (YoY) | -4.59% |
| Gross Profit | $153.91M |
| Operating Income | -$147.27M |
| Pretax Income | -$175.23M |
| Net Income | -$175.23M |
| EBITDA | -$135.12M |
| EBIT | -$147.20M |
| Reported EPS (TTM) | -$3.21 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 31.77% of the $466.04M in total assets.
| Cash and Equivalents | $95.80M |
|---|---|
| Total Debt | $0 |
| Net Cash | $95.80M |
| Net Cash Per Share | $1.47 |
| Working Capital | $253.21M |
| Shareholder Equity | $148.04M |
| Book Value Per Share | $2.27 |
| Total Assets | $466.04M |
| Total Liabilities | $318.00M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.70M of capital spending, operating cash flow left -$154.80M of free cash flow.
| Operating Cash Flow | -$152.10M |
|---|---|
| Capital Expenditures | $2.70M |
| Free Cash Flow | -$154.80M |
| FCF Per Share | -$2.35 |
| Depreciation and Amortization | $17.91M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -95.68%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -95.68% |
| Pretax Margin | -113.85% |
| Net Margin | -113.85% |
| EBITDA Margin | -87.79% |
| EBIT Margin | -95.64% |
| FCF Margin | -100.58% |
| Gross Margin (5Y Average) | 81.18% |
Growth
Revenue grew 14.78% a year over 3 years.
| Revenue Growth (3Y CAGR) | +14.78% |
|---|---|
| Revenue Growth (5Y CAGR) | +1.97% |
| Book Value Per Share Growth (2Y CAGR) | -47.07% |
| Tangible Book Per Share Growth (2Y CAGR) | -47.07% |
Dividends and Yields
RGNX does not pay a dividend. Its free cash flow yield is -32.76%.
| FCF Yield | -32.76% |
|---|---|
| Buyback Yield | -27.26% |
| Shareholder Yield | -27.26% |
Peer Position
Against 4 similar companies, RGNX has the lowest P/S.
P/S RatioPeer median 6.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 3.1x vs 6.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -4.59% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.76% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +7.76% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RGNX
What is RGNX's market cap?
Regenxbio has a market cap of $505.18M. Its enterprise value, which adds debt and subtracts cash, is $409.38M.
How many shares of RGNX are outstanding?
Regenxbio has 65.26M shares outstanding. The count is up 26.26% from a year earlier.
Does RGNX pay a dividend?
No. Regenxbio does not pay a dividend.
How much debt does RGNX have?
Regenxbio has $0 of total debt and $95.80M of cash and equivalents, a net cash position of $95.80M.
RGNX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors